The high?fidelity prostate tumor patient?derived xenograft (PDX) model is the basis for studies of iology and pharmacotherapy of prostate cancer. However, the development and application of prostate tumor has been ampered by a low success rate of transplanted primary tumors in mice as most prostate cancers are highly relevant to ormones. The high?fidelity PDX model of prostate cancer better maintains the histopathology and molecular heterogeneity f the original tumor. Here, we review the improved method of establishing PDX model of prostate cancer, including the estosterone supplementation, the quality of the original tumor tissue as well as the stromal niche, and the application of ommonly used therapeutic drugs, and to provide a theoretical basis for clinical studies of prostate tumor. These attempts re very important for development of new agents and research on mechanisms of prostate cancer. It will further promote the ndividualized treatment of prostate cancer.